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Introduction
Atrial fibrillation (AF) is the most common cardiac ar-
rhythmia, and it is a significant cause of cardiovascular 
disease and mortality worldwide1. AF incidence is pre-
dicted to increase 2 to 3 times by 20501. Patients with AF 
have a 5 times higher risk of stroke, but this risk is not 
homogeneous considering the presence of specific stroke 
risk factors / modifiers. For instance, non-paroxysmal AF 
is associated with a higher incidence of stroke compared 
to paroxysmal AF2. The most common causes of stroke in 
patients with AF are incorporated into the CHA2DS2-
VASc score, which is used to assess the risk of thrombo-
embolic (TE) incident and the decision to introduce anti-
coagulant therapy according to the latest AF treatment 
guidelines1. The introduction of anticoagulant therapy 
should be considered in men with 1, and women with 2 
points; while it is certainly indicated for men with ≥2 
points, and for women with ≥3 points according to 
CHA2DS2-VASc1. However, in addition to assessing the 
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A B S T R A C T
Concurrent spontaneous hemopericardium and hemothorax due to anticoagulant use are extremely rare in clinical 
practice. Dabigatran is an oral direct thrombin inhibitor approved to prevent stroke or thromboembolic episodes in patients 
with nonvalvular atrial fibrillation. We report the case of a 73-year-old man who received dabigatran therapy (150 mg twice 
a day) for 3 months and developed massive spontaneous hemothorax and hemopericardium associated with fever. Emer-
gency chest computed tomography scan established higher-density pericardial effusion (22HU) and left pleural effusion of 
heterogeneous density (5–15 HU) which could be hemorrhagic content while the heart ultrasound finding confirmed peri-
cardial effusion 7–9 mm thick, without affecting hemodynamics. Almost 1100 mL of blood was drained by ultrasound-
guided thoracentesis. After excluding other possible causes, diagnostic withdrawal was performed for dabigatran and no 
further pleural or pericardium effusion developed after dabigatran was discontinued. Therefore, practitioners could be 
aware of hemothorax as well as hemopericardium as a potential complication of dabigatran therapy.
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risk of TE, the risk of bleeding should initially be assessed 
with HASBLED as recommended scoring system3.
Warfarin has been the foundation of anticoagulant 
therapy used worldwide for many years. One of the main 
limitations of warfarin administration is the narrow ther-
apeutic interval assuming INR values between 2 and 3, 
the need for regular prothrombin time monitoring and 
frequent dose adjustment4. Furthermore, warfarin inter-
acts with various foods (e.g. green vegetables) and drugs, 
which affects the stability of the anticoagulant effect. The 
solution to a number of problems related to vitamin K 
antagonists has been provided by newer anticoagulant 
drugs that are increasingly used in clinical practice. Di-
rect oral anticoagulant (DOAC) therapy is the foundation 
of care for a patient with AF, largely due to a beneficial 
effect on long-term prognosis. DOAC therapy prevents 
ischemic strokes and reduces overall mortality5. All of the 
evaluated direct oral anticoagulants (DOACs) (dabiga-
tran, rivaroxaban, apixaban, and edoxaban) were either 
noninferior or superior to warfarin therapy in reducing 
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the risk of stroke or systemic embolism (SE) in patients 
with NVAF (non-valvular atrial fibrillation)6–9. However, 
bleeding that may occur during their use is a concerning 
side effect. In patients with NVAF, DOACs have a sig-
nificantly lower risk of bleeding complications as well as 
intracranial hemorrhage compared to the same cases 
treated with warfarin10. Patients treated with anticoagu-
lant drugs make up a significant percentage of patients in 
emergency departments. Their treatment is very challeng-
ing considering their increased risk of bleeding or in-
creased risk of thromboembolism in case of discontinua-
tion of anticoagulant therapy.
In this case report we describe a man with AF who 
developed both hemothorax and hemopericardium due to 
dabigatran use. 
Case Report
The 73-year-old man (height, 190 cm; body weight, 112 
kg; body mass index (BMI), 31.0 kg/m2) was admitted to 
the emergency department complaining of increased 
shortness of breath and history of subfebrile condition. He 
had a known diagnosis of NVAF with repeated cardiover-
sions in the last two months prior to this admission, chron-
ic obstructive pulmonary disease, hypothyreosis and isch-
emic cardiomyopathy with stents implanted in the 
proximal left anterior descending artery (LAD). Before 
admission, a planned electrophysiology study has been 
canceled due to unexpected fever. Approximately 3 months 
before admission, the patient had been prescribed dabiga-
tran etexilate 150 mg orally twice a day (CHA2DS2-VASc 
3 , HASBLED 3). His other drug therapy consisted of le-
vothyroxine, diuretics, tamsulosin and bisoprolol. 
In January 2019 he became subfebrile with noticed in-
crease in inflammatory parameters. Several antibiotics 
were changed, but without effect on clinical response and/
or change in biomarkers. He was conscious with hemody-
namic stability and afebrile. The clinical examination of 
the respiratory system and heart examination revealed 
reduced breath sounds and dullness to percussion at the 
left low base, with regular heart sounds, but no pathologi-
cal murmur. A summary radiological image of the thorac-
ic organs showed the left lower pulmonary field homoge-
neously shaded with applanation of the associated 
hemidiaphragm in terms of the pleural component. Emer-
gency multi-slice computed tomography (MSCT)  of the 
pulmonary artery ruled out embolization, but established 
higher-density pericardial effusion (22HU) and left pleural 
effusion of heterogeneous density (5–15 HU)  which could 
be hemorrhagic content.  The patient’s serum creatinine 
concentration at this time was 103 umol/l and hemoglobin 
level of 134 g/l together with C-reactive protein (CRP) on 
admission 131 mg/l and at discharge 30 mg/l. The patient 
was hospitalized at the Clinic for Cardiovascular Diseases 
where additional diagnostic procedures were carried out. 
The patient underwent thoracentesis in which 1100 ml of 
mild hemorrhagic effusion was drained. During hospital-
ization, dabigatran was excluded due to its probable asso-
ciation with pericardial and pleural effusions, and low 
molecular heparin was introduced. During the next ultra-
sound examination, the circumscribed effusion around the 
heart slowly receded. Patient was discharged with another 
drug from DOAC class (apixaban 5 mg twice daily) and 
after 4–5 weeks echocardiography revealed a pericardium 
without effusion and without recurrence of hematothorax. 
Through 1-year follow up period given therapy had benefi-
cial effect without subsequent complications.
Discussion 
Dabigatran is the first oral anticoagulant approved for 
AF after 50 years of using warfarin and other drugs11. It 
is a direct and competitive inhibitor of free and bound 
thrombin, with predictable pharmacokinetics. It does not 
react with food, and has little potential to react with oth-
er drugs12,13. Dabigatran half-life in the body is 12–17 h, 
therefore dosing twice a day reduces the variability of the 
anticoagulant effect13. Dabigatran has been given an ad-
vantage over previous drugs in the treatment of AF based 
on the results of the RE-LY study, which demonstrated a 
significant treatment-by-age interaction11. Compared with 
warfarin, both dosages of dabigatran (150 and 110 mg 
twice a day) were associated with minor bleeding risk in 
patients <75 years old. However, in patients ≥75 years old, 
dabigatran 150 mg twice a day was associated with a 
higher rate of major bleeding, and dabigatran 110 mg 
twice a day had a similar risk of bleeding13.
Annually 2% of AF patients receiving any anticoagu-
lant therapy have severe bleeding as a side effect1. As 
dabigatran is increasingly prescribed in the treatment of 
NVAF, the number of its adverse events has also in-
creased14. Barton et al. were the first to describe hemoperi-
cardium as a side effect of dabigatran in the United States 
in the 2012. In their paper they described a 70-year-old 
man was taking dabigatran at a dose of 150 mg twice a day 
for 2 months and consequently developed hemopericardium 
as a side effect of dabigatran14. Abdallah et al. reported a 
case of a 63-year-old man with atrial fibrillation who was 
on dabigatran 150 mg therapy. On diagnostic imaging be-
fore ablation, he was diagnosed with a large pericardial 
effusion and a left pleural effusion. This was the first case 
described in the US where the same patient had pleural 
and pericardial effusion as a side effect of dabigatran15. 
In our case an extended systematic and multidisci-
plinary investigation during hospitalisation was per-
formed. We revealed no peculiarities, and therefore all 
possible secondary causes were rejected. Our patient did 
not take any medication which inhibits CYP3A4 and CY-
P3A5 as well as P-glycoprotein or medications that inter-
act with and alter the pharmacokinetics and bioavailabil-
ity of other drugs, potentially limiting the safe use of 
dabigatran. The Thrombin Time Assay was not measured, 
and hospitals coagulometers that are currently available 
were not sensitive enough to measure Thrombin Time in 
patients receiving dabigatran. Also, we did not measure 
the dabigatran serum concentration. To our knowledge, 
both tests for monitoring coagulation cascade in patients 
receiving dabigatran are not FDA-approved. Febrile reac-
157
I. Katić et al.: Dabigatran Use in Hemopericardium and Hemothorax, Coll. Antropol. 44 (2020) 3: 155–158
tions could be explained as absorption fever during hemo-
thorax and pericardial effusion. 
In the literature, hemothorax in the setting of treat-
ment with warfarin, heparin and low molecular weight 
heparin as well as other anticoagulant therapies has been 
well-documented16–18. Most cases usually occured within 
the first week from starting the anticoagulation therapy, 
but they may also occur later in time. Moderate spontane-
ous hemothorax in the right lung after receiving 110 mg 
of dabigatran twice a day for 1.5 years has been developed 
in 72-year-old male as well as in 63-year-old woman who 
received dabigatran for 8 weeks, causing sanguineous 
pericardial effusion and left pleural effusion15,19. Our pa-
tient was exposed to a new anticoagulant, dabigatran, for 
3 months before this clinical presentation.
In our case, dabigatran led to pleural and pericardial 
effusion. Following thoracentesis, the patient was hemo-
dynamically stable and there was no need to introduce 
fresh frozen plasma or idarucizumab, a novel antidote for 
reversal of dabigatran effect, while pericardial effusion 
was monitored regularly by ultrasound without evidence 
of hemodynamic compromise. Namely, idarucizumab is 
one of available solutions that is recommended for revers-
ing the anticoagulant effect of dabigatran in life-threat-
ening bleeding due to its rapid action and its effectiveness 
in 88 to 98% of patients20,21. However, obesity influence on 
absorption, excretion, pharmacokinetics and pharmacody-
namics of various anticoagulants could be significant as-
sociation with higher risks of stroke/bleeding depending 
on DOAC subtype22,23. Evidence exists that the risk for 
ischemic stroke event amongst obese patients dabigatran 
anticoagulated are significantly higher in comparison to 
warfarin anticoagulated patients24.
Conclusion 
Our report adds to the growing evidence that DOACs 
may be associated with major bleeding consequences such 
as pleural and pericardial effusion. The aim of this case 
report was to raise awareness of possible serious bleeding 
associated with dabigatran, so that not only physicians, 
but also patients could recognize bleeding-related symp-
toms. This could facilitate prompt responses which would 
improve patient outcomes.
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TERAPIJA DABIGATRANOM KAO UZROK ISTOVREMENOG HEMOPERIKARDA I HEMOTORAKSA: 
PRIKAZ SLUČAJA
S A Ž E T A K
Istodobno spontani hemoperikard i hemotoraks tijekom primjene oralnih antikoagulanata izuzetno je rijetka pojava 
u kliničkoj praksi. Dabigatran je oralni izravni inhibitor trombina odobren za prevenciju moždanog udara ili tromboem-
bolijskih događaja u bolesnika s nevalvularnom fibrilacijom atrija. Prikazan je slučaj 73-godišnjaka na terapiji dabiga-
tranom (150 mg dva puta dnevno) od 3 mjeseca sa razvojem masivnog spontanog hemotoraksa i hemoperikarda praćeno 
vrućicom. Višeslojna kompjutorizirana tomografija (MSCT) toraksa je pokazala perikardijalni izljev veće gustoće (22HU) 
kao lijevi pleuralni izljev heterogene gustoće (5–15 HU), opisano kao mogući hemoragični sadržaj, dok je nalaz ultraz-
vuka srca verificirao perikardijalni izljev od 7–9 mm, bez utjecaja na hemodinamiku. Torakocentezom se evakuira go-
tovo 1100 ml krvi. Urađenom kliničkom obradom isključeni su drugi uzroci te se izostavljanjem dabigatrana iz terapije 
prekinulo daljnje nakupljanje krvi u perikard ili pleuralni prostor. Tijekom primjene dabigatrana moguć je potencijalni 
nastanak hemoragičnih komplikacija na koje svakako treba pomišljati. 
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